Abstract 1842P
Background
Mindfulness-Based Interventions have emerged as a promising approach to supportive care in oncology, addressing various dimensions of patients' quality of life, such as psychological distress, pain, and social support. Although some authors have already carried out qualitative analyses of the experience of participating in a mindfulness program, to our knowledge this is the first qualitative analysis conducted with patients after their participation in the Mindfulness-Based Cancer Recovery (MBCR) program.
Methods
The SERENITY study was a randomized controlled pilot study evaluating the feasibility and psychological effects of the eMBCR program for women with breast or gynecological cancer. 62 patients were randomized (2:1) to eMBCR + treatment as usual or TAU alone. They were assessed at baseline, after the intervention, and at 3-month follow-up. Assessments consisted of various psychological questionnaires, as well as qualitative interviews exploring participants’ experiences. Scores at baseline, t1, and t2 were compared between groups using Mixed Models for Repeated Measures. The qualitative analysis followed a thematic approach.
Results
Participants in the intervention group showed an improvement in the depression scale with a high-medium effect size after completion of the program. There were no significant differences between groups for the other psychological questionnaires, but most of them showed a clear trend towards improvement. At 3-month follow-up, a decrease in effect was observed for most questionnaires. In interviews, participation in the eMBCR program proved to be a safe environment, in which patients saw their well-being improve and acquired useful skills for their everyday lives. An interesting theme that emerged was that of re-exposure to memories of cancer, which in most cases was a source of positive transformation, but also a profoundly difficult experience for 4 participants.
Conclusions
Our study revealed a beneficial experience following regular mindfulness practice. We note, however, that this program could lead to difficult experiences that are important to recognize and reflect on to protect patients from these potentially deleterious effects.
Clinical trial identification
NCT04564768.
Editorial acknowledgement
Legal entity responsible for the study
Geneva University Hospitals (Hôpitaux Universitaires de Genève).
Funding
Hôpitaux Universitaires de Genève Recherche Suisse contre le cancer Fondation Leenaards Fondation NOVA.
Disclosure
S. Peters: Financial Interests, Institutional, Advisory Board: Vaccibody, Takeda, Seattle Genetics, Sanofi, Roche/Genentech, Regeneron, Phosplatin Therapeutics, PharmaMar, Pfizer, Novartis, Mirati, Merck Serono, MSD, Janssen, Incyte, Illumina, IQVIA, GSK, Gilhead, Genzyme, Foundation Medicine, F-Star, Eli Lilly, Debiopharm, Daiichi Sankyo, Boehringer Ingelheim, Blueprint Medicines, Biocartis, Bio Invent, BeiGene, Bayer, BMS, AstraZeneca, Arcus, Amgen, AbbVie, iTheos, Novocure; Financial Interests, Institutional, Invited Speaker: Takeda, Sanofi, Roche/Genentech, RTP, Pfizer, PRIME, PER, Novartis, Medscape, MSD, Imedex, Illumina, Fishawack, Eli Lilly, Ecancer, Boehringer Ingelheim, BMS, AstraZeneca, OncologyEducation, RMEI, Mirati; Financial Interests, Personal, Other, Associate Editor Annals of Oncology and Deputy Editor Lung Cancer: Elsevier; Financial Interests, Institutional, Advisory Board, Permanent independent scientific advisor: Hutchmed; Financial Interests, Institutional, Member of Board of Directors, Swiss network of pharmacies: Galenica; Financial Interests, Institutional, Coordinating PI, MERMAID-1: AstraZeneca; Financial Interests, Institutional, Steering Committee Member, MERMAID-2, POSEIDON, MYSTIC: AstraZeneca; Financial Interests, Institutional, Steering Committee Member, Clinical Trial Steering committee CheckMate 743, CheckMate 73L, CheckMate 331 and 451: BMS; Financial Interests, Institutional, Steering Committee Member, RELATIVITY 095: BMS; Financial Interests, Institutional, Steering Committee Member, BGB-A317-A1217-301/AdvanTIG-301: Beigene; Financial Interests, Institutional, Trial Chair, Clinical Trial Chair ZEAL-1: GSK; Financial Interests, Institutional, Steering Committee Member, Clinical Trial steering Committee PEARLS, MK-7684A: MSD; Financial Interests, Institutional, Steering Committee Member, Clinical Trial Steering Committee SAPPHIRE: Mirati; Financial Interests, Institutional, Steering Committee Member, LAGOON: PharmaMar; Financial Interests, Institutional, Steering Committee Member, phase 1/2 trials: Phosplatin Therapeutics; Financial Interests, Institutional, Trial Chair, Clinical Trial Chair Skyscraper-01; chair ALEX; steering committee BFAST; steering committee BEAT-Meso; steering committee ImPower-030, IMforte: Roche/Genentech; Financial Interests, Institutional, Steering Committee Member, Phase 2 Inupadenant with chemo: iTeos; Non-Financial Interests, Officer, ESMO President 2020-2022: ESMO; Non-Financial Interests, Officer, Council Member & Scientific Committee Chair: ETOP/IBCSG Partners; Non-Financial Interests, Officer, Vice-President Lung Group: SAKK; Non-Financial Interests, Other, Involved in Swiss politics: Swiss Political Activities; Non-Financial Interests, Officer, President and Council Member: Ballet Béjart Lausanne Foundation; Non-Financial Interests, Principal Investigator, Involved in academic trials: ETOP / EORTC / SAKK; Non-Financial Interests, Member: Association of Swiss Physicians FMH (CH), ASCO, AACR, IASLC; Non-Financial Interests, Leadership Role, ESMO President: ESMO; Non-Financial Interests, Member, Vice-President Lung Group: SAKK; Non-Financial Interests, Leadership Role, Vice -President: SAMO; Non-Financial Interests, Member, Association of Swiss interns and residents: ASMAC/VSAO. All other authors have declared no conflicts of interest.
Resources from the same session
1885P - Serum ATG5 protein may determine chemotherapy-related cognitive dysfunction in older patients with cancer
Presenter: Ozgur Tanriverdi
Session: Poster session 12
1886P - Expectations and priorities of older patients with cancer: The PRIORITY multicenter cohort study
Presenter: Thomas Grellety
Session: Poster session 12
1887P - Effect of logotherapy on chronic sorrow, dignity, and meaning in life of palliative care patients
Presenter: Yasemin Eskigulek
Session: Poster session 12
1888P - PalliScore: Validation of a rapid scoring system for enhancing decision-making in the Emergency Department for cancer patients in palliative care
Presenter: Rafael Carmo
Session: Poster session 12
1889P - Addressing unmet needs in the management of persistent severe cancer pain: European expert recommendations
Presenter: Mario di Palma
Session: Poster session 12
1890P - End-of-Life (EOL) systemic anticancer treatment (SACT) and health services use before and during the COVID-19 pandemic
Presenter: Javaid Iqbal
Session: Poster session 12
1891P - The effects of glucagon-like peptide 1 agonists on immune checkpoint inhibitor-associated cardiotoxicity
Presenter: Cho Han Chiang
Session: Poster session 12
1892P - Glucagon-like peptide 1 agonists and anthracycline-associated cardiotoxicity in hematologic malignancies
Presenter: Cho Hung Chiang
Session: Poster session 12
1893P - Incidence of myocardial ischemia during treatment with capecitabine: Assessment with Holter recording and cardiac biomarkers
Presenter: Anne Dyhl-Polk
Session: Poster session 12
1894P - Pulmonary function test (PFT) and circulating biomarkers in immune-related pneumonitis (irP) in advanced non-small cell lung cancer (aNSCLC): A real-world multidisciplinary experience
Presenter: Loc Carlo Bao
Session: Poster session 12